| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.045 | 0.4 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.4 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.4 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |